Baker Julian's Form 4 filing
BeOne Medicines Ltd. (ONC) · filed Dec 10, 2024
- Accession no.
- 0000950170-24-135174
- Filed
- Dec 10, 2024, 9:25 PM ET
- Trade date
- Dec 9, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $194.2M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director |
| Baker FelixCIK 0001087940 | Director |
| Baker Bros. Advisors LPCIK 0001263508 | Director |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director |
| 667, L.P.CIK 0001551139 | Director |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2024 | American Depositary Shares | SSaleDisposed | −3,074 | $208.01F11 | −$639,434.11 | 874,529 | Indirect | |
| Dec 9, 2024 | American Depositary Shares | SSaleDisposed | −33,943 | $208.01F11 | −$7,060,609.02 | 9,657,351 | Indirect | |
| Dec 9, 2024 | American Depositary Shares | SSaleDisposed | −83,036 | $186.50 | −$15,486,214 | 791,493 | Indirect | |
| Dec 9, 2024 | American Depositary Shares | SSaleDisposed | −916,964 | $186.50 | −$171,013,786 | 8,740,387 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F11
The price reported in Column 4 is a weighted average price. These American Depositary Shares ("ADS") were traded by the Funds in multiple transactions at prices ranging from $208.000 to $208.185, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
Remarks
Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP, are directors of BeiGene, Ltd. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.